Background:
Finding
malignant tumors early is important for removing them. Researchers want to find ways of doing
this with scans and genetic testing.
Objectives:
Eligibility:
Design:
They will have a magnetic resonance imaging (MRI) scan.
They will be in
the scanner for 60 90 minutes, lying still for 15 minutes at a time. Participants will
get earplugs for the loud sounds. They will get a contrast agent (dye) through a thin
plastic tube (catheter) inserted in an arm vein.
They will get radioactive glucose (sugar) through a catheter in an arm
vein.
This is like the FDG scan but with a different radioactive
chemical.
A piece of tumor tissue is removed with a needle. A piece of tissue from a
previous biopsy may also be studied.
Blood will be taken. It will be tested along with
biopsy samples. Researchers will explain the risks and procedures. They may notify
participants if testing shows health problems.
Accepts Healthy Volunteers
Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms |
No |
Study Type
An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes. An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes. Searching Both is inclusive of interventional and observational studies. |
Interventional |
Eligible Ages | 10 Years - 99 Years |
Gender | All |
Trial ID:
This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries. |
NCT02211768 |
Phase
Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans. Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data. Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use. |
Phase 1 |
Lead Sponsor
The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data. |
National Cancer Institute (NCI) |
Principal Investigator
The person who is responsible for the scientific and technical direction of the entire clinical study. |
Brigitte C Widemann, M.D. |
Principal Investigator Affiliation | National Cancer Institute (NCI) |
Agency Class
Category of organization(s) involved as sponsor (and collaborator) supporting the trial. |
NIH |
Overall Status | Recruiting |
Countries | United States |
Conditions
The disease, disorder, syndrome, illness, or injury that is being studied. |
Neurofibromatosis, MPNST |
Study Website: | View Trial Website |
If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.